This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.
Have an increased waist-to-height ratio of ≥0.5
Have at least one pre-obesity-related complication (prediabetes, prehypertension, predyslipidemia)
Have at least one unsuccessful attempt to reduce body weight based on diet and exercise
Have a BMI greater than or equal to 25 to less than or equal to 29.9 kg/m2 or equivalent-/region-specific overweight thresholds
Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
Do not have a stable body weight within 90 days before screening
Have a documented obesity diagnosis or self-reported history of BMI ≥30 kg/m² (or an equivalent region-specific threshold)
Have taken medications for weight loss, including over-the counter medications or alternative therapies, within 180 days prior to screening
Parallel
Orforglipron
DrugAdministered orally
Placebo
DrugAdministered orally
Time to Onset of Obesity Related Complications or Class 1 Obesity
Obesity related complications defined as type 2 diabetes, hypertension, or dyslipidemia; Class 1 obesity defined as body mass index (BMI) ≥30 kilograms per square meter (kg/m2) or an equivalent region-specific threshold
Percent Change from Baseline in Body Weight
Time to Onset of Waist-to-Height Ratio ≥0.6
Change from Baseline in Waist Circumference
Time to Onset of Class 1 Obesity
Click on the lead sponsor to view all of their trials.
